Similarly, in the ALK-negative ALCL PDX model, the combination of the two drugs significantly improved therapeutic efficacy compared to single-agent treatment without weight loss (Fig. 5B, D, Supplementary Fig. S7H). Here, ALK is linked to anaplastic large cell lymphoma.